UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

_____________

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of report (Date of earliest event reported): May 10, 2017

STRATA SKIN SCIENCES, INC.

(Exact Name of Registrant Specified in Charter)

Registrant's telephone number, including area code:   215-619-3200

N/A

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐      Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐      Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐      Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐      Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))    

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Item 5.02.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On May 10, 2017 James Coyne accepted the invitation extended to him on May 2, 2017 by the Board of Directors of STRATA Skin Sciences, Inc. (the "Company") to become a member of the Company's Board of Directors. In addition to his regular duties as a Board member, Mr. Coyne will serve as a member of the Board's Compensation Committee. Mr. Coyne is currently the CEO of Modevity LLC, a software company he founded in 2004, and which produces the ARALOC™, a market leading digital content distribution program.

The appointment of Mr. Coyne took place on the same day that the Company accepted the resignation of Dr. R. Rox Anderson from his position as a Board member and member of the Board's Audit Committee. Even though the demands on his time from his professional obligations made it untenable for Dr. Anderson to continue to serve as Board member and member of the Audit Committee, he intends to remain directly involved with the Company as the head of its newly reconstituted Scientific Advisory Board.

Ms. Luann Via, a long-standing member of the Company's Board, has become a member of the Audit Committee.

In connection with this event, the Company issued a press release, a copy of which is attached as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01               Financial Statements and Exhibits

Exhibit No.            Exhibit Description

99.1                              Press Release dated May 10, 2017

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date:  May 10, 2017

Exhibit Index

Exhibit No.          Exhibit Description

99.1                              Press Release dated May 10, 2017

 

---

STRATA Skin Sciences, Inc. Announces the Appointment of James L. Coyne to its Board of Directors

Dr. R. Rox Anderson Steps Down as Board Member and will head the STRATA Skin Sciences, Inc. Scientific Advisory Board

Horsham, PA – May 10, 2017 -- STRATA Skin Sciences, Inc. (NASDAQ: SSKN) ("STRATA"), a medical technology company in Dermatology and Plastic Surgery dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announced the appointment of James L. Coyne to its Board of Directors. STRATA's product offerings include the XTRAC excimer laser, the STRATApen MicroSystem, and the Nordlys multi-technology aesthetic laser.

Jeffrey F. O'Donnell, Chairman of the STRATA Board, stated, "We are excited to have Jim Coyne join as our newest Board member. Jim has over 20 years of experience as both a CEO and an entrepreneur having successfully guided the development, growth and exits of several products and companies. As the Chief Executive Officer for privately held Modevity, LLC, Jim has provided leadership and vision in developing Modevity's software products, including those in the life sciences and education fields."

Mr. O'Donnell continued, "Jim's breadth of experience and knowledge in marketing and selling technology products and services will bring a tremendous advantage to STRATA as we continue our growth to be the business partner of choice to physicians in the dermatologic, cosmetic and aesthetics fields."

Mr. O'Donnell also stated, "We are sorry that the demands of Dr. Anderson's professional duties no longer allow him the time he would like to devote to STRATA as a member of our Board of Directors. However, at the same time we are excited to have such a world-renowned expert in the fields of dermatology and photomedicine head up our newly reconstituted Scientific Advisory Board.   Dr. Anderson's experience with XTRAC goes back many years, and he led the team that developed the first XTRAC system at Massachusetts General Hospital. He has been at the forefront of a number of major discoveries and developments in the science of photomedicine."

About STRATA Skin Sciences, Inc. (www.strataskinsciences.com)

STRATA Skin Sciences is a medical technology company focused on the therapeutic and aesthetic dermatology market. Its products include the XTRAC^® laser and VTRAC^® excimer lamp systems utilized in the treatment of psoriasis, vitiligo and various other skin conditions; the STRATAPEN™ MicroSystem, marketed specifically for the intended use of micropigmentation which utilizes the patent-pending Biolock™ cartridge; and Nordlys, a multi-technology aesthetic laser device.

Safe Harbor

This press release includes "forward-looking statements" within the meaning of the Securities Litigation Reform Act of 1995. These statements include but are not limited to the Company's plans, objectives, expectations and intentions and may contain words such as "will," "may," "seeks," and "expects," that suggest future events or trends. These statements are based on the Company's current expectations and are inherently subject to significant uncertainties and changes in circumstances. Actual results may differ materially from the Company's expectations due too financial, economic, business, competitive, market, regulatory and political factors or conditions affecting the Company and the medical device industry in general, as well as more specific risks and uncertainties set forth in the Company's SEC reports on Forms 10-Q and 10-K. Given such uncertainties, any or all of these forward-looking statements may prove to be incorrect or unreliable. The Company assumes no duty to update its forward-looking statements and urges investors to carefully review its SEC disclosures available at www.sec.gov and www.strataskinsciences.com.

Investor Contacts:

Christina L. Allgeier, Chief Financial Officer

STRATA Skin Sciences, Inc.

callgeier@strataskin.com

215-619-3267

Bob Yedid, Managing Director

LifeSci Advisors, LLC

bob@LifeSciAdvisors.com

646-597-6989

 

 

---